This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aldeyra Therapeutics Inc (ALDX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Aldeyra Therapeutics Inc (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aldeyra's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aldeyra Therapeutics.
Company News for Apr 15, 2020
by Zacks Equity Research
Companies in the news are: WFC, FAST, FRC, ALDX
What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock
by Zacks Equity Research
Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
by Zacks Equity Research
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock
by Zacks Equity Research
Aldeyra (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) shares rose nearly 8% in the last trading session, amid huge volumes.
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap
by Zacks Equity Research
Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
Sucampo Pharmaceuticals (SCMP) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
Sucampo Pharmaceuticals(SCMP) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) saw a big move last session, as its shares jumped more than 34% on the day, amid huge volumes.
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
by Zacks Equity Research
Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
by Zacks Equity Research
Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
by Zacks Equity Research
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
by Zacks Equity Research
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.
AstraZeneca Sells Marketing Rights to Seloken in Europe
by Zacks Equity Research
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.